No Data
No Data
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript Summary
Agios Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.
Agios Pharmaceuticals | 10-Q: Quarterly report
Agios Pharmaceuticals GAAP EPS of $16.22 Beats by $7.53, Revenue of $8.96M Misses by $0.54M
Agios Pharmaceuticals: Q3 Earnings Snapshot